A Phase 2 interventional study of BI 456906 and Placebo in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 80 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-29.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim — 2 open to participants now, 3 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Boehringer Ingelheim.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, this one is the 41st largest by enrollment of the 96 interventional ones that give a count, is one of 5 that started in 2020, is one of 18 in phase 2, and was the 116th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Australia, Canada and 3 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 48 more countries
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 413 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 302 across the 96 interventional studies, 10,286 across the 34 observational. Of the 125 that completed or were terminated, 109 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05882071Boehringer IngelheimNon-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 130 studies in Diabetes Mellitus, Type 2 by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight.
Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are put into 7 groups. The participants in groups 1 to 6 get injections under the skin once or twice every week. Some participants get different doses of BI 456906 and other participants get placebo. Placebo injections look like the BI 456906 injections, but contain no medicine. Participants in group 7 get semaglutide injections every week. Semaglutide is another medicine for adults with type 2 diabetes.
During the study, the doctors regularly take blood samples from the participants and measure their body weight. The changes in blood sugar levels and body weight are compared between the groups. The doctors also check the general health of the participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Continuous oral pharmacotherapy to treat any clinical condition during the Trial. Following medications are allowed:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BI 456906
Drug: BI 456906
Drug: BI 456906
Drug: BI 456906
Drug: BI 456906
Drug: BI 456906
Drug: Semaglutide
Drug: Placebo
Solution for Injection
Solution for Injection
Solution for Injection
Absolute Change in HbA1c From Baseline to 16 Weeks
Absolute change in glycosylated hemoglobin A1c (HbA1c) from baseline to 16 weeks after treatment start is presented. The measurements for this outcome were performed at baseline and at Week 17. Absolute change from baseline in HbA1c to 16 weeks after treatment start was calculated by subtracting the baseline HbA1c value from the HbA1c value at Week 17.
Time frame: At baseline and at Week 17 (16 weeks after treatment start).
Key Secondary Endpoint: The Relative Change in Body Weight From Baseline to 16 Weeks
The relative change in body weight from baseline to 16 weeks after treatment start is presented. The measurements for this outcome were performed at baseline and at Week 17. The relative change in body weight from baseline to 16 weeks after treatment start was calculated as (body weight at Week 17 - body weight at baseline/body weight at baseline) \* 100.
Time frame: At baseline and at Week 17 (16 weeks after treatment start ).
The Absolute Change in Body Weight From Baseline to 16 Weeks
The absolute change in body weight from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17. The absolute change in body weight from baseline to 16 weeks after treatment start was calculated as: body weight at Week 17- body weight at baseline.
Time frame: At baseline and at Week 17 (16 weeks after treatment start).
The Absolute Change in Waist Circumference From Baseline to 16 Weeks
The absolute change in waist circumference from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17. The absolute change in waist circumference from baseline to 16 weeks after treatment start was calculated as: waist circumference at Week 17- waist circumference at baseline.
Time frame: At baseline and at Week 17 (16 weeks after treatment start).
Percentage of Patients With 5 % or Greater Body Weight Loss From Baseline to 16 Weeks
The percentage of patients with 5 percent (%) or greater body weight loss from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17.
Time frame: At baseline and at Week 17 (16 weeks after treatment start).
Percentage of Patients With 10% or Greater Body Weight Loss From Baseline to 16 Weeks
The percentage of patients with 10 % or greater body weight loss from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17.
Time frame: At baseline and at Week 17 (16 weeks after treatment start).
This was a randomized, multicenter placebo and active comparator controlled, double-blind within dose groups, parallel-group, 16-week trial in patients with type 2 diabetes mellitus (T2DM). An open-label arm (semaglutide) was included as benchmark to compare response curves and support assumptions for Phase III design.
| Milestone | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| Started | 60 | 50 | 50 | 52 | 50 | 51 | 50 | 50 |
| Treated | 59 | 50 | 50 | 52 | 50 | 51 | 49 | 50 |
| Completed | 49 | 41 | 45 | 36 | 33 | 45 | 37 | 45 |
| Not completed | 11 | 9 | 5 | 16 | 17 | 6 | 13 | 5 |
| Withdrew: Other than listed | 2 | 2 | 0 | 1 | 0 | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 3 | 1 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Adverse event | 3 | 5 | 5 | 11 | 15 | 4 | 8 | 2 |
| Withdrew: Not treated | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Absolute change in glycosylated hemoglobin A1c (HbA1c) from baseline to 16 weeks after treatment start is presented. The measurements for this outcome were performed at baseline and at Week 17. Absolute change from baseline in HbA1c to 16 weeks after treatment start was calculated by subtracting the baseline HbA1c value from the HbA1c value at Week 17.
| percentage (%) of HbA1c | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| Absolute Change in HbA1c From Baseline to 16 Weeks | -0.23 ± 0.81 | -0.91 ± 0.71 | -1.37 ± 0.93 | -1.79 ± 0.92 | -1.67 ± 0.78 | -1.68 ± 0.90 | -1.79 ± 0.76 | -1.50 ± 0.84 |
The relative change in body weight from baseline to 16 weeks after treatment start is presented. The measurements for this outcome were performed at baseline and at Week 17. The relative change in body weight from baseline to 16 weeks after treatment start was calculated as (body weight at Week 17 - body weight at baseline/body weight at baseline) \* 100.
| percentage of body weight change | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| Key Secondary Endpoint: The Relative Change in Body Weight From Baseline to 16 Weeks | -1.20 ± 3.52 | -1.86 ± 2.91 | -4.43 ± 3.92 | -6.63 ± 5.13 | -6.68 ± 4.05 | -7.16 ± 6.06 | -8.95 ± 5.33 | -5.40 ± 4.33 |
The absolute change in body weight from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17. The absolute change in body weight from baseline to 16 weeks after treatment start was calculated as: body weight at Week 17- body weight at baseline.
| kilogram (kg) | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| The Absolute Change in Body Weight From Baseline to 16 Weeks | -1.28 ± 3.05 | -1.90 ± 3.12 | -4.41 ± 4.07 | -6.31 ± 4.53 | -6.88 ± 4.41 | -6.75 ± 6.10 | -8.88 ± 4.93 | -5.18 ± 4.52 |
The absolute change in waist circumference from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17. The absolute change in waist circumference from baseline to 16 weeks after treatment start was calculated as: waist circumference at Week 17- waist circumference at baseline.
| centimeter | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| The Absolute Change in Waist Circumference From Baseline to 16 Weeks | -1.95 ± 9.08 | -2.73 ± 10.49 | -1.80 ± 10.55 | -3.63 ± 10.94 | -7.47 ± 12.24 | -4.61 ± 9.73 | -12.89 ± 25.50 | -3.63 ± 5.05 |
The percentage of patients with 5 percent (%) or greater body weight loss from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17.
| percentage of patients | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| Percentage of Patients With 5 % or Greater Body Weight Loss From Baseline to 16 Weeks | 6.8 | 8.0 | 38.0 | 42.3 | 46.0 | 56.9 | 57.1 | 38.0 |
The percentage of patients with 10 % or greater body weight loss from baseline to 16 weeks after treatment start is presented. Measurements for this outcome were performed at baseline and at Week 17.
| percentage of patients | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| Percentage of Patients With 10% or Greater Body Weight Loss From Baseline to 16 Weeks | 0.0 | 2.0 | 6.0 | 13.5 | 16.0 | 25.5 | 34.7 | 16.0 |
Collected over From first intake of any trial drug until last intake of any trial drug (planned: 16 weeks) + residual effect period (BI 456906: 28 days, Semaglutide: 35 days), up to 159 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/59 (0%) | 3/59 (5.1%) | 18/59 (30.5%) |
| BI 456906 0.3 mg | 0/50 (0%) | 1/50 (2%) | 27/50 (54%) |
| BI 456906 0.9 mg | 0/50 (0%) | 4/50 (8%) | 30/50 (60%) |
| BI 456906 1.8 mg | 0/52 (0%) | 3/52 (5.8%) | 40/52 (76.9%) |
| BI 456906 2.7 mg | 0/50 (0%) | 2/50 (4%) | 33/50 (66%) |
| BI 456906 1.2 Twice Weekly (2.4) mg | 0/51 (0%) | 1/51 (2%) | 33/51 (64.7%) |
| BI 456906 1.8 Twice Weekly (3.6) mg | 0/49 (0%) | 0/49 (0%) | 37/49 (75.5%) |
| Semaglutide | 0/50 (0%) | 0/50 (0%) | 20/50 (40%) |
| Event | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| CellulitisInfections and infestations | 0/59 | 0/50 | 2/50 | 0/52 | 0/50 | 0/51 | 0/49 | 0/50 |
| Abdominal painGastrointestinal disorders | 0/59 | 1/50 | 0/50 | 0/52 | 0/50 | 0/51 | 0/49 | 0/50 |
| DiarrhoeaGastrointestinal disorders | 0/59 | 0/50 | 0/50 | 0/52 | 1/50 | 0/51 | 0/49 | 0/50 |
| Irritable bowel syndromeGastrointestinal disorders | 0/59 | 0/50 | 1/50 | 0/52 | 0/50 | 0/51 | 0/49 | 0/50 |
| Mouth ulcerationGastrointestinal disorders | 0/59 | 0/50 | 1/50 | 0/52 | 0/50 | 0/51 | 0/49 | 0/50 |
| VomitingGastrointestinal disorders | 0/59 | 1/50 | 0/50 | 0/52 | 0/50 | 0/51 | 0/49 | 0/50 |
| Autoimmune disorderImmune system disorders | 0/59 | 0/50 | 1/50 | 0/52 | 0/50 | 0/51 | 0/49 | 0/50 |
| ViraemiaInfections and infestations | 0/59 | 0/50 | 0/50 | 0/52 | 1/50 | 0/51 | 0/49 | 0/50 |
| Pharyngeal ulcerationRespiratory, thoracic and mediastinal disorders | 0/59 | 0/50 | 1/50 | 0/52 | 0/50 | 0/51 | 0/49 | 0/50 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/59 | 0/50 | 0/50 | 0/52 | 0/50 | 1/51 | 0/49 | 0/50 |
| Event | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/59 | 10/50 | 14/50 | 25/52 | 23/50 | 14/51 | 23/49 | 6/50 |
| Decreased appetiteMetabolism and nutrition disorders | 2/59 | 6/50 | 7/50 | 6/52 | 11/50 | 9/51 | 15/49 | 3/50 |
| VomitingGastrointestinal disorders | 3/59 | 7/50 | 9/50 | 12/52 | 13/50 | 6/51 | 11/49 | 2/50 |
| DiarrhoeaGastrointestinal disorders | 7/59 | 12/50 | 8/50 | 9/52 | 7/50 | 8/51 | 11/49 | 5/50 |
| ConstipationGastrointestinal disorders | 0/59 | 3/50 | 2/50 | 7/52 | 7/50 | 8/51 | 5/49 | 3/50 |
| DyspepsiaGastrointestinal disorders | 0/59 | 4/50 | 3/50 | 5/52 | 4/50 | 4/51 | 7/49 | 1/50 |
| Abdominal distensionGastrointestinal disorders | 2/59 | 3/50 | 1/50 | 1/52 | 6/50 | 2/51 | 4/49 | 1/50 |
| Weight decreasedInvestigations | 0/59 | 0/50 | 1/50 | 2/52 | 0/50 | 6/51 | 4/49 | 1/50 |
| FatigueGeneral disorders | 0/59 | 3/50 | 1/50 | 3/52 | 2/50 | 4/51 | 5/49 | 1/50 |
| HeadacheNervous system disorders | 4/59 | 4/50 | 5/50 | 4/52 | 1/50 | 3/51 | 5/49 | 0/50 |
Treated set (TS): TS included all patients who were randomized and received at least one dose of study drug.
| Age, Continuous(Years) | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 57.5 ± 10.5 | 56.1 ± 10.2 | 58.2 ± 9.6 | 55.3 ± 10.3 | 59.6 ± 8.5 | 58.3 ± 8.8 | 57.7 ± 9.4 | 55.8 ± 10.5 | 57.3 ± 9.8 |
| Sex: Female, Male(Participants) | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 28 | 24 | 22 | 25 | 17 | 24 | 22 | 16 | 178 |
| Male | 31 | 26 | 28 | 27 | 33 | 27 | 27 | 34 | 233 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 15 | 11 | 8 | 12 | 12 | 10 | 9 | 14 | 91 |
| Not Hispanic or Latino | 44 | 39 | 42 | 40 | 38 | 41 | 40 | 36 | 320 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Asian | 8 | 4 | 5 | 8 | 4 | 5 | 3 | 5 | 42 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 3 | 3 | 1 | 2 | 2 | 4 | 3 | 2 | 20 |
| White | 47 | 42 | 44 | 42 | 43 | 41 | 42 | 43 | 344 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Glycosylated hemoglobin A1c (HbA1c) measured in percentage units [%](percentage of HbA1c) | Placebo | BI 456906 0.3 mg | BI 456906 0.9 mg | BI 456906 1.8 mg | BI 456906 2.7 mg | BI 456906 1.2 Twice Weekly (2.4) mg | BI 456906 1.8 Twice Weekly (3.6) mg | Semaglutide | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 8.15 ± 0.85 | 8.09 ± 0.76 | 7.89 ± 0.80 | 8.14 ± 0.86 | 8.18 ± 0.97 | 8.11 ± 0.94 | 7.97 ± 0.71 | 8.03 ± 0.82 | 8.07 ± 0.84 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.
Data sharing details ↗ · www.mystudywindow.com
Ran from Apr 2020 to primary completion in Oct 2021, 17 months.
Results were first posted in Nov 2022, 1 year 1 month after primary completion. A results delay was requested in Sep 2022.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 17 months is above that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Survodutide